NASDAQ: AZN

Explore the latest insights on NASDAQ: AZN and its impact on China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of NASDAQ: AZN’s developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

NMPA Approves Lilly's Jaypirca (Pirtobrutinib) as First‑Line Monotherapy for CLL/SLL – Non‑Covalent BTK Inhibitor Completes Line‑of‑Therapy Progression in China
CompanyDrug

NMPA Approves Lilly’s Jaypirca (Pirtobrutinib) as First‑Line Monotherapy for CLL/SLL – Non‑Covalent BTK Inhibitor Completes Line‑of‑Therapy Progression in China

Eli Lilly and Company (NYSE: LLY) announced that China's National Medical Products Administration (NMPA) has officially approved a new indication for its non‑covalent (reversible) BTK inhibitor Jaypirca (pirtobrutinib), as a…

Sino Biopharmaceutical's CTTQ Partners With STADA on Pembrolizumab Biosimilar TQB3570 – Exclusive European License With Options Across Oncology and Immunology

Sino Biopharmaceutical’s CTTQ Partners With STADA on Pembrolizumab Biosimilar TQB3570 – Exclusive European License With Options Across Oncology and Immunology

Sinovac and Egypt's GENNVAX Launch sIPV Technical Cooperation Project in Beijing – Sabin Inactivated Polio Vaccine Localization Deal Enters Implementation Phase

Sinovac and Egypt’s GENNVAX Launch sIPV Technical Cooperation Project in Beijing – Sabin Inactivated Polio Vaccine Localization Deal Enters Implementation Phase

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
CompanyDrug

AstraZeneca’s Calquence Receives Conditional Approval in China for MCL

CompanyDeals

3SBio Terminates Distribution Agreement with AstraZeneca for Byetta

CompanyDrug

Enhertu Approved in China for HER2-Positive Breast Cancer

CompanyDrug

AstraZeneca’s Calquence Administered in Hainan Ahead of Official Approval

CompanyDeals

Lepu and Keymed License CLDN18.2 ADC CMG901 to AstraZeneca

Company

AstraZeneca Reports Q4 and Full-Year 2022 Results with Strong Revenue Growth

CompanyDeals

Meheco’s Genertec Partners with AstraZeneca for COVID-19 Antibody Evusheld in China

CompanyDrug

Kelun-Biotech’s SKB264 Approved for Phase II Study in EGFR-Mutant NSCLC

Show More